4.8 Article

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

Related references

Note: Only part of the references are listed.
Article Medicine, General & Internal

Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin A Randomized Trial

John P. H. Wilding et al.

ANNALS OF INTERNAL MEDICINE (2012)

Article Pharmacology & Pharmacy

Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

B. Komoroski et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)

Article Endocrinology & Metabolism

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

James F. List et al.

DIABETES CARE (2009)

Article Endocrinology & Metabolism

Association Between Serum Uric Acid and Development of Type 2 Diabetes

Satoru Kodama et al.

DIABETES CARE (2009)

Editorial Material Medicine, General & Internal

Rosiglitazone no longer recommended

[Anonymous]

LANCET (2008)

Article Endocrinology & Metabolism

Serum uric acid is associated with micro albuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitus

Michiaki Fukui et al.

METABOLISM-CLINICAL AND EXPERIMENTAL (2008)

Article Cardiac & Cardiovascular Systems

Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome

TW Yoo et al.

CIRCULATION JOURNAL (2005)